Latest Updates

Stay up on the latest exciting news and updates from the Defeat GBM Research Collaborative.

Publications based on Defeat GBM research findings:

  1. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS (2014) Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 11 (4): 255-263. DOI: 10.7497/j.issn.2095-3941.2014.04.004.
  2. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee, WK, Furnari FB. Mischel PS (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science, 343 (6166): 72-76. DOI: 10.1126/science.1241328.
  3. Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee, WK (2014) Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. Cancer Research, 74 (5): 192-205. DOI: 10.1158/0008-5472.CAN-13-2117.
  4. Li J, Zhu S, Kozono D, Ng K, Futalan D, Shen Y, Akers JC, Steed T, Kushwaha D, Schlabach M, Carter BS, Kwon CH, Furnari F, Cavenee W, Elledge S, Chen CC (2014) Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 5 (4): 882-93. DOI: 10.18632/oncotarget.1801.
  5. Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL (2014) Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling. Oncogene. 34 (31): 4078-88 DOI: 10.1038/onc.2014.336.
  6. Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY (2014) EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest.124 (9): 3741-3756. DOI: 10.1172/JCI73093.
  7. Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C, Mellinghoff IK (2014) A kinase-independent function of AKT promotes cancer cell survival. Elife. 3. DOI: 10.7554/eLife.03751.
  8. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK, Furnari FB. (2015) A Urokinase Receptor-Bim Signaling Axis Emerges During EGFR Inhibitor Resistance in Mutant EGFR Glioblastoma. Cancer Res. 75 (2): 394-404. DOI: 10.1158/0008-5472.CAN-14-2004.
  9. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E (2015) Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 125 (4): 1591-1602. DOI: 10.1172/JCI78239.
  10. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS (2015) Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc. Natl. Acad. Sci. 112 (30): 9406-11. DOI: 10.1073/pnas.1511759112.
  11. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy, TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS (2015) EGFR Mutation Promotes Glioblastoma Through Epigenome and Transcription Factor Network Remodeling. Mol. Cell 60 (2): 307-318. DOI: 10.1016/j.molcel.2015.09.002.
  12. Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF (2016) Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget. 7 (18): 26793-805. DOI: 10.18632/oncotarget.8471.
  13. Wu S, Wang, S, Zheng S, Verhaak R, Koul D and Yung WK (2016) MSK-1 Mediated beta catenin phosphorylaton confers resistance to PI3K/mTOR inhibitors in glioblastoma. Mol Cancer Ther.15 (7): 1656-68. DOI: 10.1158/1535-7163.MCT-15-0857.
  14. De la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB (2016) Integration of R-2HG-Proton MRS into clinical practice for disease monitoring in IDH-mutant glioma. Neuro Oncol. 18 (2):283-90. DOI: 10.1093/neuonc/nov307.
  15. Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, Larson SM, Mellinghoff IK (2016) Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight.1(6): pii: e87030.
  16. Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF (2016) Evaluating Cancer of the Central Nervous System through Next-Generation Sequencing of CSF. J Clin Oncol. 34 (20): 2404-15. DOI: 10.1200/JCO.2016.66.6487.
  17. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B (2016) Single-Cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in Glioblastoma. Cancer Cell. 29 (4): 563-73. DOI: 10.1016/j.ccell.2016.03.012.
  18. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H3, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz PI, Gahman TC, Shiau AK, Cravatt BF, Mischel PS (2016) An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 30 (5): 683-693. DOI: 10.1016/j.ccell.2016.09.008.
  19. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson D, Kornblum HI, Taylor MD, Kausal S, Cavenee WK, Wechsler-Rena R, Furnari FB, Vandenberg S, Rao PN, Wahl GM, Bafna V, Mischel PS (2017) Extrachromosomal Oncogene Amplification Drives Tumor Evolution and Genetic Heterogeneity. Nature, 543 (7643): 122-125. DOI: 10.1038/nature21356.
  20. Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG (2017) Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol. 13(2): 914. DOI: 10.15252/msb.20167159.

Reviews

  1. Masui K, Cavenee WK, Mischel PS (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab. 25 (7): 364-373. DOI: 10.1016/j.tem.2014.04.002.
  2. Nichol D, Mellinghoff IK. (2015) PI3K pathway inhibition in GBM—is there a signal? Neuro Oncol. 17 (9): 1183-4. DOI: 10.1093/neuonc/nov124.
  3. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS (2015) Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 15 (5): 302-310. DOI: 10.1038/nrc3918.
  4. Thorne AH, Zanca, C Furnari F (2016) Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. 18 (7): 914-918. DOI: 10.1093/neuonc/nov319.
  5. Lassman, AB, Cloughesy TF (2016) Biomarkers in NOA-04: another piece to the puzzle. Neuro Oncology 18 (11): 1467-1469. DOI: 10.1093/neuonc/now210.
  6. Masui K, Cavenee WK, Mischel PS (2016) Cancer metabolism as a central driving force of glioma pathogenesis. Brain Tumor Pathol. 33 (3): 161-8. DOI: 10.1007/s10014-016-0265-5.
  7. Masui K, Shibata N, Cavenee WK, Mischel PS (2016) mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling. Bioessays 38 (9): 839-44. DOI: 10.1005/bies.201600026